tions offered guidance on its execution; however, international divergence left many questions unanswered. These differences in the literature caused EAACI to initiate a task force to answer unmet needs and find a consensus in executing nasal allergen challenge. On the basis of a systematic review containing nasal allergen challenges of the past years, task force members reviewed evidence, discussed open issues, and studied variations of several subjective and objective assessment parameters to propose a standardized way of a nasal allergen challenge procedure in clinical practice. Besides an update on indications, contraindications, and preparations for the test procedure, main recommendations are a bilaterally challenge with standardized allergens, with a spray device offering 0.1 mL per nostril. A systematic catalogue for positivity criteria is given for the variety of established subjective and objective assessment methods as well as a schedule for the challenge procedure. The task force recommends a unified protocol for NAC for daily clinical practice, aiming at eliminating the previous difficulty of comparing NAC results due to unmet needs.
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| INTRODUCTION
Allergic rhinitis is one of the most debilitating diseases of our times: It is estimated that 500 million people worldwide (20% of the population) are affected by symptoms of allergic rhinitis, leading to severe health impairment and increased medical costs, as well as decreased work force and man power due to sick leave/down times. Furthermore, frequent comorbidities such as asthma, eczema, food allergies, rhinosinusitis, and other reactions significantly contribute to the burden of this disease.
A correct diagnosis is essential for adequate therapy. A thorough history, physical examination, and allergy tests (including skin prick test and specific serum IgE) can lead the way. However, allergen challenge tests are a safe and straightforward technique and recommended in order to identify phenotypes of the disease or to identify those allergens against which specific allergen immunotherapy is a promising option. 
| Objective
After one decade of using nasal allergen challenge (NAC) on the basis of existing guidelines and publications, 2,3 a unified and internationally consented version is presented here. There are some discrepancies and unmet needs in existing important papers. This leads to difficulties when comparing results between studies using NAC. 4, 5 Unmet needs on unifying methodologies are, for example, allergen dose and quality, allergen application technique, the need of a titration process, provocation of either 1 or 2 nostrils, or the best methods to assess subjective and objective outcomes. 4, 5 Recently published position papers have mentioned NAC 6,7 but lack a unified guideline how to utilize it in daily practice. We aimed at providing a guideline for the daily use of NAC in common clinical practice.
| Definition
Nasal allergen challenge (NAC) reproduces an allergic reaction of the nose under standardized and controlled conditions. 8 This simple, safe, and cheap technique has been internationally established in many countries as a standard procedure to diagnose allergic rhinitis.
9,10
Applying an allergen to the nasal mucosa provokes an immediate Manual explorations of the reference lists of these 786 studies were performed and relevant studies identified by 3 independent reviewers. Studies were considered for evaluation in this position paper if they included a nasal application of a specific standardized allergen in human subjects. A clinical nasal patency test including symptom scores or objective measurement had to be part of the outcome parameter.
In the end, 173 papers meeting all criteria were selected ( Figure 1 , Literature research). TF members reviewed the selected studies with special attention to existing guidelines. 3, 12, 13 They had the possibility to suggest also other publications than the studies previously identified, in case these were likewise matching the criteria listed above. The methods and results of those papers were summarized in Table S1 (body of evidence).
During 5 meetings and international conferences, task force members met to elaborate this position paper and to find answers for unmet needs. Online discussions throughout this course completed the opinion finding process. Some of the recommendations were based on consensus-driven proposals from the TF working group. ).
Several nasal pathologies can affect nasal patency. This may lead to technical difficulties in assessing the outcome of an allergen challenge. Therefore, it is very important to assess baseline conditions of nasal function before provocation. The pathologies affecting nasal patency include the following:
• Choanal atresia 12 • Chronic rhinosinusitis with nasal polyps 47 • Septal perforation and severe septal deviation 3, 12 • Atrophic rhinitis • Adenoids obstructing nasal ventilation
| Test day/seasonality
Besides patient's history, the skin prick test or serum-specific IgE values should be completed and their results present in order to evaluate specific sensitizations to ensure the right indication and the correct allergen to be tested.
Several studies have shown that previous exposure to allergens can affect nasal patency. [48] [49] [50] [51] [52] Using seasonal allergens, NAC should 
| Room conditions
Allergen challenges cannot fully replace real-life studies. It is thus necessary to provide a controlled test environment to achieve reproducible results. Thus, environmental variations should be avoided, 6 T A B L E 1 Levels of evidence and grades of recommendation
Level of evidence
Level I Systematic reviews, meta-analysis, randomized controlled trials Level II Two groups, nonrandomized studies (e.g., cohort, case-control)
Level III One-group nonrandomized (e.g., before and after, pretest, and post-test)
Level IV Descriptive studies that include analysis of outcomes (single-subject design, case-series)
Level V Case reports and expert opinion that include narrative literature, reviews, and consensus statements
Grades of recommendation o Persisting allergic rhinitis 16, 17 o Intermittent allergic rhinitis 17, 18 o Local allergic rhinitis [19] [20] [21] [22] [23] [24] [25] [26] o Occupational rhinitis [27] [28] [29] [30] • Correlation with extranasal symptoms 31, 32 • Differential diagnosis of ocular symptoms 33 • Further Evidence diagnosing food allergy 34, 35 • To design allergen composition and to monitor clinical efficacy of immunotherapy [36] [37] [38] [39] Contraindications Absolute contraindications:
• Previous anaphylactic reaction to the allergen • During an acute inflammation of the nose or paranasal sinuses 13, 40, 41 • Severe comorbidities (e.g., cardiopulmonary diseases, impairment of lung capacity 3, 40 )
• Extremely high grade of sensitization (e.g., severe and uncontrolled bronchial asthma or chronic obstructive pulmonary disease 3, 40 )
• Other severe systemic diseases (e.g., malignant tumors, autoimmune diseases 42 )
• Systemic immunotherapy • During pregnancy 3, 40 Relative contraindications:
• Infants under the age of 5 43, 44 • Unstandardized allergen extracts due to a lack of comparability and reproducibility
Temporary contraindications:
• Acute allergic reactions in other organs 12 • Vaccination (wait 1 wk) 12 • Acute viral or bacterial infection (wait 4 wk) 45 • Surgery of the nose or paranasal sinuses (postpone for 6-8 wk) 40 • Recent use of alcohol or tobacco for 24-48 h before NAC 3 and NAC should be performed under standardized room conditions, including previous exposition, acclimation time, room temperature, and humidity. 54 For a proper implementation, patients should be well adapted to the climatic conditions of the examination room. 54 While conditions are best controlled using allergen exposure chambers, room conditions in NAC with spray devices need standardization. 54 The room must not be contaminated by other substances (methacholine, test puffs of the allergen spray, etc.). Mandatory test puffs (if using a spray) must be conducted in another room, under a hood, or against a gauze/cotton pad for better test accuracy and patient safety. 12 In addition, various emotional stimuli may influence nasal mucosal swelling, such as simple communication with the patient or a person entering the room. Therefore, such stimuli should be avoided, 55 and a calm and quiet atmosphere should be assured. We recommend a 
| Emergency medication
Although it has never been reported, an anaphylactic reaction can occur after nasal allergen challenge. Therefore, patients should sign an informed, written consent document before undergoing the test. Expiration dates of lyophilisates, solutions and control solutions should be checked before application. The specific summary of product characteristics (SPC) should be adhered to for the specific products used.
After being stored in the refrigerator at 4°C, the allergen solution should be brought to room temperature to avoid mucosal irritation.
There are different manufacturers of allergen provocation solutions on the market. Numerous concentration units (SQ-U/mL, SBU/ mL, AU/mL, HEP/mL, or w/v %) unfortunately make it impossible to compare the allergen concentration of the different allergen solutions. Besides, TF members determined a decreasing availability of nasal challenge allergen products in European countries due to registration barriers.
Literature research has shown that SQ-U/mL is the quota/unit used by most of the studies (see Table S1 ). However, the TF members do not recommend one of the manufacturers units but support the usage of SI units, for example, in lg/mL major allergen content.
We refer to the Standard Summary of Medicinal Product Characteristics (SMPCs) of the manufacturers for the clinical use of allergens in NAC. This may not be the case for scientific evaluations.
Allergen titration should be limited to research settings, therapy control (testing the response to certain treatments, if continuation of therapy needs to be decided), dose finding processes (to determine the sensitivity threshold of each allergen in research settings), 61 or patients with extremely high grades of sensitization, in whom the standardized concentration might evoke anaphylaxis and asthma attacks. 
| Application of allergens
Several methods for allergen application have been used in the past.
Pump-aerosol spray has been claimed to be the easiest and most reliable device available. 10 Dispensing an exact amount of solution, usually 50 lL/puff, it can be applied without irritation of the mucosa. 4, 7 The Task Force recommends an allergen application by spray bottles with a 50 lL/puff nozzle. There is a risk of depositing the allergen in the pharynx, which may cause irritation of the lower airways. In daily practice, this risk can easily be avoided by giving precise instructions to the patient during the challenge procedure.
| Application technique for spray devices
We concur with the predominant opinion to bilaterally challenge and assess nasal patency (Level of evidence V, grade of recommendation
.
Fifty-nine of the 173 investigated studies used a defined amount of 0.1 mL allergen solution (see Table S1 -body of evidence). Implementing a test puff ensures that the medication chamber of the spray device contains the full amount of solution and dispenses the proper amount of aerosol. The advantage of a test puff is also the higher reproducibility of studies.
Based on the device used, the allergen should be applied by giving 2 puffs (of 0.05 mL per puff) per nostril, one in the inferior meatus and one on the direction of the middle turbinate. This technique aims to cover the mucosa of the inferior and middle portion of the nasal mucosa with the test allergen. It should be avoided to spray toward the nasal septum to prevent mechanical irritation. 4, [62] [63] [64] The precise instructions are to take a deep breath before, hold breath during, and exhale profoundly after application of the allergen. 4, 12 This technique prevents aerosol penetration of the lower respiratory tract via the nasopharynx, which is one possible adverse event of NAC.
| Subjective/semiquantitative measurement
In a systematic review, Andr e et al concluded that comparing subjective and objective assessments of the nasal airways show every possible combination of strong, weak, or even inverse correlations. In addition, objective measurements cannot predict the subjective feeling reported by patients. 65 Subjective and objective parameters assess different aspects of nasal obstruction. Therefore, nasal obstruction should be evaluated in combination with at least one subjective and one objective parameter [66] [67] [68] and assessing clinical symptoms should be set as the most relevant outcome parameter in allergen challenges. 3, 9, 12, 69 Other semiquantitative methods such as counting sneezes or weighing nasal secretions are valid, yet seem less practicable and reliable.
| Symptom scores
There are different semiquantitative, subjective measures to evaluate nasal symptoms, for example, reporting organ-related symptoms on a
Likert scale (0 = none, 1 = mild, 2 = moderate, or 3 = severe) 70 or visual analog scales (VAS) 71, 72 with the latter reporting the severity of symptoms on a 0-to 100-mm horizontal scale (mild: 0-30 mm; moderate: 31-70 mm; and severe: 71-100 mm). 10 Total Nasal Symptom Score (TNSS) is a 12-point scale derived by summing scores for 4 symptoms (rhinorrhea, nasal obstruction, sneezing, and nasal itching). Assessed in a Likert scale, the maximum TNSS scores are 12 points.
The task force members concurred that the ideal subjective scale would contain the following 5 symptoms: sneezing, nasal pruritus, rhinorrhea, nasal obstruction, and ocular symptoms. These key symptoms are also included in Linder and Lebel scores. [73] [74] [75] According to the ARIA guidelines, the use of VAS in reporting congestion, sneezing, itching, and rhinorrhea by patients with a vertical line on a scale between 0 and 100 mm is a clear and easy-to-use method for measuring severity of allergic rhinitis. 76 Demoly et al showed in nearly 1000 patients that a simple VAS 71 They are also frequently reported as being complementary to other measurements. 6, 66, 71, 78 However, there is a high degree of heterogeneity on which (organ-specific) symptoms to assess by VAS (see Table S1 ).
A standardized visual analog Scale (VAS) (Level of evidence I, grade of recommendation A 72 ) as suggested by ARIA was the main opinion of TF members to be used as subjective measure. This scale is a self-assessment of patients' symptoms and should be filled in by patients, assisted by the investigator evaluating the symptoms sneezing, rhinorrhea, or ocular symptoms together.
| Objective assessment of nasal patency
Various technical methods to assess and objectify nasal airflow and • Active anterior rhinomanometry (AAR) is a sensitive, highly specific method and currently accepted as international standard method for objective nasal patency measurements.
82
• 4-phase-rhinomanometry (4PR) is reported to be the most reliable technical method to assess nasal ventilation and patency, as well as the nasal valve region. 83 The consensus of this TF was to accept all above-mentioned, objective, and established methods and concurs that one criterion suffices to diagnose a positive NAC, if it is strongly positive. NAC results can be seen as positive in the following way (Figure 2 ):
• Strong increase in objective measurement = O or • Strong increase in subjective symptoms = S or • moderate increase in two criteria (objective and subjective measurement) = o + s
| Outcome interpretation
When interpreting the reaction after nasal allergen challenge, there are various valid measures to be used, which are summarized in Table 3 .
| Challenge procedure and timing
The actual challenge procedure can be divided into 3 steps of measurements, containing a baseline measurement, a control challenge, and the allergen challenge, subjectively and objectively assessing nasal ventilation at each step.
In the first (baseline) measurement, nasal ventilation should be assessed before any substance has been applied to compare results of the control challenge and allergen challenge with the initial value.
As some allergen solutions contain preservatives that may react with the nasal mucosa, it is then necessary to perform a control challenge with the same diluent that is used to prepare the allergen solutions. Such hyper-reactivity may occur in all types of rhinitis. 84 The German and Spanish guidelines 3, 12 To have optimal comparability of the control challenge with the allergen reaction, timing of assessment should also be unified. In previous recommendations and papers, 10 or 15 minutes has been used. 4, 12 Control challenge scores should be evaluated 10 minutes 
| Follow-up
The patient should be kept under observation for at least half an hour until the reaction ceases. 44 The task force suggests the use of standardized test solutions, to spray 2 puffs (0.1 mL per nostril) bilaterally and to evaluate clinical results of the challenge both subjectively and objectively.
Despite the co-existence of several equally validated methods to conduct NAC, it was the aim of this task force to provide a standardized, more user-friendly protocol of NAC for daily, clinical practice.
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